Secondary Logo

November/December 2018 - Volume 41 - Issue 9
pp: 385-425

The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell–mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells

Merz, Christian; Sykora, Jaromir; Marschall, Viola; More

Journal of Immunotherapy. 41(9):385-398, November/December 2018.

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma

Tavera, René J.; Forget, Marie-Andrée; Kim, Young Uk; More

Journal of Immunotherapy. 41(9):399-405, November/December 2018.


Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy

Liu, Yanfen; Chen, Xinfeng; Wang, Dao; More

Journal of Immunotherapy. 41(9):406-410, November/December 2018.

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product

Lindenberg, Melanie A.; Retèl, Valesca P.; van den Berg, Joost H.; More

Journal of Immunotherapy. 41(9):413-425, November/December 2018.